Insulin pump and CGM leader MiniMed (MMED.US) makes its debut on the US stock market - "Medtronic Plc halo" can't outweigh growth concerns.

The soon-to-be spun-off diabetes management company MiniMed Group Inc, from US healthcare giant Medtronic Plc, has successfully raised around 560 million US dollars through its initial public offering (IPO), although the offering price was lower than its previous expected range, highlighting discounting in the medical technology niche market and market valuation discounting for MiniMed under Medtronic, and uncertainty about future growth. According to a statement on Thursday, the leading American healthcare company sold 28 million shares at a price of $20 per share. A previous unrevised filing had indicated that the company planned to set the offering price between $25 and $28 per share. At this latest IPO price, based on the number of shares listed in its filing, the California-based healthcare company in Norwich is expected to have a preliminary market value of around 5.6 billion US dollars. MiniMed's main business focuses on selling automatic insulin pumps, continuous glucose monitoring devices, and smart insulin pens. As a diabetes management business unit under Medtronic, its product line mainly includes the MiniMed series of fully automated insulin pumps, continuous glucose monitors (CGM), and smart insulin pens, all designed, developed, and manufactured by MiniMed/Medtronic themselves rather than simply acting as agents or resellers. The flagship products of the MiniMed series such as the 780G, 670G automated insulin infusion systems are the company's proprietary technology platforms, which integrate sensors, control algorithms, and hardware terminals, and achieve automated insulin management through closed-loop control technology. They have obtained FDA and other regulatory approvals and clinical applications in global markets. MiniMed's main business covers product development, clinical validation, production manufacturing, and market sales through integrated operations based on MiniMed's own medical technology and product achievements, rather than relying on third-party brands or traditional OEMs. The diabetes-focused organization focusing on diabetes management is set to be spun off after nearly 25 years of collaboration with Medtronic, according to a letter included in the filing from CEO Que Dallara. The proposed IPO valuation has sparked a debate among Wall Street analysts about whether its growth prospects can justify these low numbers. According to adjusted EBITDA forecasts, the company's potential valuation is very cheap compared to other publicly traded companies, such as Dexcom Inc., Insulet Corp., and Tandem Diabetes Care Inc., for whom MiniMed represents a significant discount figure. In the six months ending on October 24, MiniMed's total revenue was approximately 1.5 billion US dollars, with a net loss of approximately 21 million US dollars. In comparison, in the same period of the previous year, revenue was approximately 1.3 billion US dollars, with a net loss of 23 million US dollars, indicating a narrowing loss but not strong revenue growth overall. MiniMed is expected to use some of the funds to repay a huge debt owed to Medtronic, according to the data disclosed in the filing. Goldman Sachs, Bank of America, Citigroup, and Morgan Stanley are the main underwriters for this offering. The company's stock IPO pricing was completed on the Nasdaq Stock Exchange and will subsequently be traded on the Nasdaq Global Select Market, with the proposed stock code being MMED. Although the diabetes devices segment that MiniMed's core business is in has long-term growth potential (such as insulin pumps and continuous glucose monitoring systems benefiting from an aging population and chronic disease management needs) and has accumulated technological expertise, investors have evidently taken a cautious stance towards its valuation and prospects, and there has not been a comprehensive funding frenzy. The US IPO pricing of MiniMed is lower than the previously expected range, reflecting the lack of obvious overheating signs in the market for such segmented medical stocks. This cautious market sentiment is largely due to the recent escalation of geopolitical tensions in the Middle East, greatly cooling market risk appetite, as well as the low-risk exposure and market conditions in the medical device industry over the long term. On one hand, MiniMed has shown only slight revenue growth in the past few quarters and still has a net loss record, with profitability paths not yet fully stable, hence investors have shown caution in pricing. On the other hand, compared to similar device companies such as Dexcom, Insulet, etc., its valuation is seen as discounted, showing that the capital market is more cautious in evaluating growth and risks.